Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
"Another trial due to start in Q4 2022, finish recruiting in Q3 2023, with results due H2 2024".
I missed that one. Such a trial and timeframe - was that quoted by the company?
Manifesto
Agreed, although maybe RM is quite comfortable taking his hefty wage and just gearing up for the next round of research, rather than facing the pressures that commercialisation might bring?
The RNSs have been downplayed and poorly constructed imo. Is there ever a bullish remark made by him? Always ‘maybe’ or ‘if this happens’ or ‘if we can’.
If you get a response from Brooke, you’ve done better than me.
I’m in a pretty negative mindset of this company currently; the only problem is I’m stuck for the LT.
ATB.
Thank you for doing that Mani, keep it up.
I think most of us knew instantly how huge the news was on Monday and how quick it propelled us back onto the same stage as every other therapeutic out there that's been EUA'd (as far as I know, it doesn't get much better than 70% on top of standard of care). We've found the holy grail of the statistically significant 70% improvement on top of standard of care result. It's a miraculous result and better than anything I ever expected. I'm still absolutely shocked at how good the result is.
The SP slip is something I completely understand. Traders taking profits aside, I don't think anyone cares anymore even if our result was a 100% improvement - unless the board tell us what they plan on doing with that statistic. And a slight hint - a platform trial due to end in 2024 or early 2025 won't be the answer that people are looking for.
@Manifesto - finally on my page. I have also emailed the company, RM, Brooke etc this morning.
IMHO....
IF I was not invested here and did not know in detail about SNG001 and the SPRINTER
trial, I would not have been able to understand the significance of the GREAT news
that we released last Monday...... Where was the bullish statement at the start of
the RNS from our CEO to say how pleased they were with the Deep Dive and just a few
lines to tell the reason why? There was NO comment at all from RM.... !!!
I have invested in a lot of pharma stocks over many years and when they have good
news to announce you know it from the first few lines of the RNS....
RM and Co. are letting invetsors down in this respect and need to realise
that how you communicate in a RNS matters, just rolling out % is
not enough as many potential investors are not Scientists so
the significance needs to come with a brief explanation...
Most who post here understood the relevance and what it could
mean commercially, but many who were attracted by the
sudden rise and read the RNS probably did not. We have
benefitted a few pence from significant results...
I have communicated my thoughts to Brooke!
Fully agree Axe.
Let's give them some time for the company update meeting and the AGM by which time they should have let us all know of the direction they wish to steer us back to the forefront and how they're going to do it. If we don't get this by the AGM I believe we all need to start talking about what we're going to do about the situation because I haven't come across a single person who has invested in this company who is happy with they way they've handled and communicated things over the past few weeks.
It's been a pathetic engagement with their shareholders, especially after the fundraise. I understand that they're likely quiet because talks are still ongoing and who knows what they're about (platform trials, EUA, JVs, TOs, who knows), and I'm sure we're all more than willing to give them the time and space to sort all of that out. But there's a difference between giving them the time and space and being left completely in the dark - and that's what I won't be standing for either.
LOL. Some people on here… beggars belief.
We are listed on AIM. For those that don’t realise, the ‘I’ is for INVESTMENT. We’re not giving money to charity here. We’re investing in a company to make money. And invest we did when SNG asked for £80m from us all. As shareholders, we have a right to know what is going on. Communication has been appalling.
I’m willing to wait to see what the company has to say next week but if nothing by the AGM, it would be right for questions to be asked.
I do think we’ll get something next week, though. They announced simultaneously that deep dive would be shown and a company update a week later. Got to be more than a coincidence.
I agree xae all they give us is results no forward planning, no information on are next steps absolute northing going forward.
They don't answer emails they need to tell the share holders what they have planed with are money this is a very poor company with communicating with the shareholders.
agreed.. too academic/research and apparently incapable of showing commercial awareness. Very sad.
Bang on Axe, the lack of updates from this company is truly staggering.
What Pivotal News wass that then? Did I miss something. All I have seen is the scientific way they reached the stats, but they basically informed the Market and us of that weeks ago.
The share price reflects that as of this morning does it not? Pivotal my a***.
The only pivotal thing so far has no back-up comms released and this is dragging the SP back down. And that is my whole point.
Deep Dive to provide back-up to previous statements, BUT no apparent immediate efforts to inform on where we go next. Which should of happened in tandem. Again snails pace and based on fact share price collapsed for us all you would think (having spent 50 million) there would be some urgency to get the positive PIVOTAL Message out there!
Hear hear fruits.
Well said Fruits.
The landscape of coronavirus has changed dramatically and trials fail. Get over it and focus on the pivotal news from ATS.
An NIH-funded trial doesn't require a boardroom shuffle. One is not contingent on the other.
The only people I see benefitting from short-term agitation are those who it best serves -> short -term punters and P&D merchants. The board is awash with both, has been since H2 2020. I expect they'll retreat under their rocks after the AGM, the usual howl and scowl crew.
I think you're right Doc. Last years was notified on a specific RNS, for June 18th and was a "closed meeting"
Sativa - I don’t think the AGM is next Wednesday. Just a financial update and general company update.
Hopefully the direction (and leadership) of the company will be clarified next Wednesday at the AGM.
One might reasonably expect a boardroom shuffle and a US trial funded by NIH, which together with the overdue Activ2 data set should trigger a stable re-rate. I would not be surprised to see a TR1 posted early next week too (MMs appear to be tree shaking).
Brand, I don’t think anyone expected £1.75 on the back of the deep dive and ATS presentation. But perhaps a bit more than 26p to 28p!
Update your Google search to last 7 days and search the term SNG001 OR synairgen - You'll see it repeated over and over again. (Along with many new positive articles on the sprinter update, which is nice to see).
We are all investors here and yes that does mean we own a very small part of the company, but if the company is going to have its message break through in to the mainstream, that means they need to concentrate on getting info Infront of new eyes, which means repeating the same message over and over. Building up the positive mentions on the web over time for maximum impact and SEO
Monday's presentation really could not have gone better from a Comms pov. The failure to meet endpoints was clearly and scientificly addressed and the deep dive data was overwhelmingly positive.
The line in the sand has been drawn. The company is now able to shout 'it works for the sickest patients' from the rooftops and they have delivered this message in person to the most important audience (hint, it's not shareholders)
If you were under the impression that after Monday we would be straight back to 1.75+ well, all I can say is this was a bit naieve. There were way too many short term holders for that. But if you are planning on seeing this journey through to the end, Monday was a seminal day in this story.
Onwards and upwards
Dumb
I know. It is so hard for LTHolders. But for new investors, at these prices - with all the available data - and Polygon, at least at the moment, providing a floor for the sp (which is what everyone has been saying) - for new investors, its a different game.
Doc
Agreed that the article is a joke.
What is also a joke is the lack of comms from the company.
They have always been so poor at responding to emails, putting out supporting tweets, providing updates for investors, etc.
I would say an email of this nature should be sent to Brooke, but I didn’t receive a reply to my last two attempts.
Is it too much to expect a tweet about how the conference is going, anything learnt, any networking news, the mood, etc. if there’s nothing to tweet or mention from such a positive event then …?
Very amateur; unfortunately I’m stuck in this for a long time.
GLA LTHs.
Genuine question: what pressure could the likes of Polygon and major shareholders apply and how would they usually do this? (charge into RMs office banging the table? "Quiet" word on the golf course?)
* I should add - I get your frustration though Axe
Well said Docdaneeka, yesterday's results should have been all over the US & UK mainstream and financial press today. Maybe its a hot topic amongst the scientific community at the ATS, but the lack of media coverage feels like another missed opportunity.
Given all the concern over SoC / steroids 70% really is astonishing.
I think this is one we're going to just have to be patient with and trust the Synairgen team (and hope large shareholders are applying pressure). Cream rises to the top, but the lack of a sp rise was surprising.
Axe is fundamentally right though. They took money from us (80 million?) at 1.75 to commercialise this product. Now, refusing to take the basic steps needed to try and get us some of that back.
Remember, Synairgen fundraised of private investors to get a lot of what they have. Refusing to engage with the commercial side and talk to investors is not merely incompetent but borderline unethical given what people lost.